21ьз╕ C

Alexandria Real Estate Equities, Inc. Named One of the Most Charitable Companies in America by Newsweek

News Provided by PR Newswire2026-03-11

Alexandria Real Estate Equities, Inc. Named One of the Most Charitable Companies in America by Newsweek

[11-March-2026]

PASADENA, Calif., March 11, 2026 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, today announced that it has been named one of the Most Charitable Companies in America by Newsweek. Alexandria is within the initial cohort of companies presented with this inaugural award, which was developed and compiled in collaboration with the publication's market research partner, Statista, based on results of an independent survey of approximately 18,000 U.S. residents who rated companies' philanthropic activities, support of local or community based organizations, active contributions to social good beyond business interests, and a reputation for being honest and ethical, as well as an examination of online media sentiment, social impact, volunteering, and analysis of key performance indicators.

"We are honored to be recognized as one of America's Most Charitable Companies by Newsweek. This consequential designation reinforces our steadfast commitment as a mission-driven company to create and grow clusters that advance human health. Combined with our multi-year recognition as one of the Most Trusted Companies in America, it attests to the strength of our one-of-a-kind brand and differentiated business model that have earned us the trust of the world's leading life science companies," said Joel S. Marcus, executive chairman and founder of Alexandria Real Estate Equities, Inc. "Guided by our extraordinary culture of idea meritocracy, integrity, mutual respect, transparency, and teamwork, our best-in-class team takes great pride in our noble contributions to combat some of the nation's most urgent challenges, including disease and the mental health epidemic, supporting our military and our nation's heroes, and driving educational opportunities. Catalyzing the health, wellness, safety, and productivity of our tenants, employees, communities, and the world at large drives everything we do."

Since its inception as a garage startup in 1994, Alexandria has been at the vanguard of the life science industry's incredible innovation and its endeavor to extend and save lives; and with 10,000 known diseases, over 90% of which still have no approved treatments, there continues to be immense growth potential for the future and the call-to-action for cross-sector collaboration is more important than ever. In 2025, Alexandria received the Charles A. Sanders, MD, Partnership Award from the Foundation for National Institutes of Health (FNIH). This historic award recognizes the company's significant contributions to the FNIH's work in accelerating biomedical innovation, epitomized by Alexandria's leadership in catalyzing a mission-critical public-private partnership with the FNIH to build a precision medicine framework for depression to address the urgent need for new, more effective medicines for patients. The first-of-its-kind initiative is being developed in collaboration with the National Institute of Mental Health, the U.S. Food and Drug Administration, and the U.S. Department of Veterans Affairs, as well as leading research institutions, cutting-edge life science entities, and patient advocates. The bold program aims to pave the way for a future where major depressive disorder is effectively treated at an individual level, rather than by a one-size-fits-all approach.

Alexandria is dedicated to developing and implementing scalable, long-term solutions to some of the most consequential societal issues to make a lasting impact on the health and vitality of its communities. By uniting the passion and dedication of its world-class team with that of its community partners, the company drives positive change through its impactful corporate social responsibility efforts, focused on (1) accelerating medical innovation to save lives, (2) harnessing agtech to combat hunger and improve nutrition, (3) supporting our military, our veterans and their families, (4) revolutionizing addiction treatment, (5) building principled leaders through education, (6) inspiring future generations with stories and values of our nation's heroes, and (7) prioritizing the mental health crisis.

About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500^® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus^™ ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of December 31, 2025, Alexandria has a total market capitalization of $20.75 billion and an asset base in North America that includes 35.9 million RSF of operating properties. Alexandria has a long-standing and proven track record of developing Class A/A+ properties clustered in highly dynamic and collaborative Megacampus environments that enhance our tenants' ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. For more information on Alexandria, please visit www.are.com.

Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding Alexandria's impact on the development of novel medicines, treatments, therapies, and cures and on human health and well-being; Alexandria's thought leadership, collaborations, investments, and progress relating to the treatment of depression; the launch, goals, and efforts of the MAP-D program; the likelihood of continued commitment and efforts by Alexandria to foster collaboration that improves human health; and Alexandria's ability to meet and anticipate industry needs and maintain strategic relationships. These forward-looking statements are based on Alexandria's present intent, beliefs, or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by Alexandria's forward-looking statements as a result of a variety of factors, including, without limitation, the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update this information. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria's forward-looking statements, and risks and uncertainties to Alexandria's business in general, please refer to Alexandria's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q.

CONTACT: Paula Schwartz, Managing Director, Rx Communications Group, (917) 633-7790, pschwartz@rxir.com